Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world. Hepatic resection or liver transplantation is the radical method to cure the disease. However, due to large tumors, surgical treatment is suitable for early-stage and well-reserved liver function patients. Therefore, in clinical practice, transarterial chemoembolization (TACE) is a preferential and standard treatment of potentially resectable HCC. EACH trial opened the door to FOLFOX-based system chemotherapy for advanced HCC patients. Recently, investigators have showed that hepatic arterial infusion of FOLFOX-based chemotherapy (HAIC) was safe and efficient for HCC patients. Several clinical studies showed that HAIC bring better tumor response rate that the conditional TACE. The combination of TACE with HAIC (TACE-HAIC), theoretically can significantly increase the local doses of chemotherapeutic agents in the liver, reduce the viability of HCC cells and increase the hepatectomy rate. However, this hasn't been verified in clinical application. To identify a more effective and safety way for treating potentially resectable HCC patients, this study is designed to compare the safety and efficacy between HAIC and TACE-HAIC for those patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
240
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
RECRUITINGprogression-free survival
Time to progression, last follow-up or death after random assignment to TACE-HAIC or HAIC
Time frame: 6-12 months
overall survival
time to death or last follow-up after random assignment to TACE-HAIC or HAIC
Time frame: 6-12 months
Downstage hepatectomy rate
The hepatectomy rate after TACE-HAIC or HAIC
Time frame: 6-12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.